Skip to main content
CBDY
OTC Life Sciences

Target Group's Cash Drops to $5,914 as Losses Double and Debt Defaults

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.001
Mkt Cap
$740.431K
52W Low
$0.001
52W High
$0.003
52W Position info
71% above low
Off High info
60% below high
Rel. Volume info
2.7× avg
Market data snapshot near publication time

CBDY sits 71% above its 52-week low of $0.001 on elevated volume (2.7× avg).

Summary

Target Group's Q2 2026 filing reveals cash of just $5,914, a net loss that doubled to $790,168, and a $7.3 million related-party loan in default — a sharp deterioration from the prior quarter.


Key Events · Earnings and Guidance · CBDY

  • Cash Nearly Exhausted

    Cash fell to $5,914 as of June 30, 2026, from $100,410 at December 31, 2025. Total cash and restricted cash is only $14,006.

  • Net Loss More Than Doubles

    Six-month net loss was $790,168, up from $327,983 in the prior-year period, driven by higher interest expense and lower gross profit.

  • Related-Party Loan in Default

    The $7,334,333 CLI loan is in default and classified as a current liability. No payments were made during the period, and terms are under renegotiation.

  • Working Capital Deficit Widens

    Working capital deficit increased to $11,232,219 from $11,052,097 at year-end, reflecting growing current liabilities.


Analysis · CBDY · Life Sciences

Target Group's second-quarter report shows a rapidly deteriorating financial position. Cash has fallen to just $5,914, down from $100,410 at year-end, while the six-month net loss more than doubled to $790,168. The company's working capital deficit widened to $11.2 million, and its related-party CLI loan of $7.3 million is now in default and due on demand. With only $14,006 in total cash and restricted cash, the company's ability to continue operations without immediate financing is severely constrained. The going-concern warning from the prior quarter is now backed by concrete numbers showing the runway is nearly exhausted.

At the time of this filing, CBDY was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $740.4K. The 52-week trading range was $0.00 to $0.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CBDY - Latest Insights

CBDY
May 15, 2026, 4:58 PM EDT
Filing Type: 10-Q
Importance Score:
9
CBDY
Mar 31, 2026, 4:55 PM EDT
Filing Type: 10-K
Importance Score:
9